Human recombinant lipocortin 1 has been tested for anti-inflammatory activity in a conventional model of acute inflammation. Microgram amounts of the protein, locally administered, inhibited edema of the rat paw when induced by subplantar injections of carrageenin: the ED50 was 10-20 fig
inactive against edema elicited by bradykinin, serotonin, platelet-activating factor-acether, or dextran, whereas edema caused by Naja mocambique venom phospholipase A2 was strongly inhibited by lipocortin. The protein inhibited edema when rats were pretreated with agents that depleted mast-cell amines, kininogen, or polymorphonuclear leukocytes prior to initiation ofthe carrageenin edema but had no inhibitory action when rats were pretreated with the dual cyclooxygenase/ lipoxygenase inhibitor BW 755C. These results demonstrate that human recombinant lipocortin has potent local antiinflammatory activity, probably through selectively interfering with eicosanoid generation. Lipocortin is relatively ineffective against edema caused by mast-cell degranulation or kinins, except when degranulation is caused by phospholipase A2.
The lipocortins (1) are a family of proteins that can inhibit phospholipase A2 activity in in vitro systems. Partially purified preparations of these proteins inhibit the release of eicosanoids (2) and lyso-platelet-activating factor (3) from cells and inhibit carrageenin-induced pleurisy (4) and paw edema in the rat (2) , but lack of a highly purified protein has curtailed more definitive experimental work.
Recently, one form of lipocortin, designated lipocortin 1, has been sequenced, and the human gene has been cloned (5) . We have reported that this recombinant protein blocks the release of eicosanoids from the guinea pig perfused lung (6) and other (7) preparations, and we now demonstrate that microgram doses of the protein, locally administered, inhibit the eicosanoid-but not the amine-dependent component of carrageenin edema in the rat paw assay. Lipocortin retains activity in this test when animals are depleted of amines or of kininogen but does not retain activity when eicosanoid synthesis is blocked. Lipocortin is also inactive as an inhibitor of edema caused by agents that degranulate mast cells or by the products of mast-cell degranulation. Only when the latter is induced by injection of phospholipase A2 is lipocortin effective.
Our results show that lipocortin has strong anti-inflammatory properties and that these properties are related to the ability of the protein to decrease eicosanoid formation at the inflammation site. Our results also suggest that lipocortin can neutralize the effect of extracellular phospholipases.
MATERIALS AND METHODS Lipocortin 1. Recombinant lipocortin 1 was produced in Escherichia coli and chemically purified (>99%) by procedures analogous to those described (5, 8) using P150 gel exclusion chromatography as the final purification step. Lipocortin was dissolved in 25 mM Tris HCl buffer, pH 7.7, with 0.1-5 mM EDTA and bovine serum albumin at 0.1 mg/ml (Pierce, endotoxin poor). The endotoxin level in the final preparation (as estimated by the limulus assay) was such that rats received 1 ng of E. coli endotoxin per 10 ,g of injected lipocortin.
Lipocortin was aliquoted in solutions of high concentration, frozen, and when thawed, used immediately. Two batches of lipocortin, designated batch A and batch B, were used in this study. The two batches varied in potency; batch A was about two to three times as potent as batch B, probably because of heterogeneity in the N terminus, the folding, or the oxidation state of the different preparations.
Carrageenin Paw Edema. Adult male Wistar rats (150-200 g) were used throughout this study. A 2% (wt/vol) solution of lambda carrageenin (Sigma) in saline (0.9% NaCl) was prepared freshly for each experiment. Before injection, a stock solution of lipocortin (1 mg/ml) was thawed and diluted in saline; the EDTA was then titrated with calcium chloride. A subplantar injection of 0.1 ml of carrageenin was followed immediately by lipocortin (or vehicle or other solution) injected in a vol of 0.1 ml (at the same injection site when possible) into the right hind paw of lightly anesthetized rats (ether). The final concentration ofcarrageenin in the injection was therefore 1% in a vol of 0.2 ml.
Paw volumes were measured hourly for up to 5 hr using a hydroplethysmograph (Socrel, Varese, Italy) , and the increase in volume caused by the irritant was estimated after subtracting the basal volume of the paw before injection.
Depletion Experiments. In depletion experiments we followed the protocols as published by Di Rosa et al. (9, 10) . In some experiments all depleting agents were used concurrently, and the dosing regimes were combined.
To deplete mast-cell amines, rats received six doses of compound 48/80 at 0.6 mg/kg i.p. at 12 hourly intervals followed by two doses of the same agent at 1.2 mg/kg, after which edema was initiated in the usual way by injection of carrageenin.
For the depletion of kininogen, rats were lightly anesthetized and injected repeatedly i.v. with cellulose sulfate at 1 mg/kg (Sigma) at 10-min intervals. After the third dose, rats were removed from the anesthesia chamber and assayed for edema not less than 3 hr later.
To be depleted of polymorphonuclear leukocytes, rats were given methotrexate at 2.5 mg/kg each day for 3 days and assessed on the fourth day for carrageenin-caused paw edema.
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Phospholipase A2 Edema. In these experiments edema was induced in the rat paw by subplantar injection of a phospholipase A2 purified from Naja mocambique mocambique (EC 3.1.1.4) (Sigma). In initial experiments a dose-response relationship between edema and amount of venom enzyme was established by injecting the hind paw with 5-30 Ag in a vol of 0.1 ml. The 10-and 30-pg doses produced the same degrees of edema (-0.75 ml at 30 min), differing only in time taken for the edema to subside. The 5-pug dose was -80%o of maximal, declined more rapidly, and was used for the remainder of our studies. The inflammogenic properties of the venom phospholipase were greatly increased by calcium addition, and we routinely dissolved the venom in a solution containing 1 mM CaCl2 before use.
Before injection, the venom was incubated for 15 min at 370C with either lipocortin or vehicle. Aliquots containing 5 gg of venom in 0.1 ml were injected into the paw, and the increase in volume was determined, as described above.
Induction (Table 2 ). Indomethacin and BW 755C in doses that completely suppress eicosanoid formation were also without effect in these tests, whereas invariably glucocorticoids inhibited markedly (see Table 2 ).
For compound 48/80, however, lipocortin produced a small (35.9 + 5.1%, n = 11), but significant (P < 0.001), inhibition at the time of maximal edema, as did 40 ,g of indomethacin (28.2 ± 5.0%, n = 10; P < 0.001). These data strongly suggest that eicosanoids were involved at the time of maximal edema as well as mast-cell amines. Again, dexamethasone inhibited the edema at all time points (see Fig. 2 ).
Edema Produced by Phospholipase A2. In 81 of85 rats tested lipocortin, in doses of 2-20 ,ug (batch B) premixed with phospholipase A2, inhibited the formation of phospholipase edema. Maximal inhibition varied with the batch of enzyme, but inhibition never exceeded 85% and was always achieved with equimolar ratios of lipocortin to phospholipase. Increasing the ratio beyond 1:1 produced no further inhibition. Fig. 3 represents a typical experiment with a single batch of venom enzyme; it shows the time course of edema produced by injecting 5 ,ug of the venom phospholipase and the dose-dependent inhibition produced by preincubating for 15 min with 5 and 10 ,ug of human recombinant lipocortin 1. The maximal inhibition achieved in this assay, as determined by inactivation of the venom enzyme with a 10-fold molar excess of p-bromophenacyl bromide before injection was 76.9 ± 4.9% (one experiment with 10 rats).
DISCUSSION
Our data demonstrate that human recombinant lipocortin 1 possesses anti-inflammatory properties in a well-characterized model of acute inflammation and supports an earlier contention regarding the biological activity of this protein (2, 4) . In a series of parallel experiments (data not shown) we tested locally administered indomethacin as an inhibitor of carrageenin-induced paw edema and determined the ED50 to be 30 jig (84 nmol). As the ED50 for lipocortin is -0.54 nmol, lipocortin is >150-fold more active on a molar basis at the 3-hr time point than is indomethacin. In doses as high as 5 mg/kg orally (which completely suppress prostaglandin production) indomethacin produced a maximal inhibition of 62.8 ± 2.7% (n = 30) of carrageenin edema at the 3-hr time point-a maximum very similar to that of lipocortin. ,tg of lipocortin given locally (n = 11); and *, dexamethasone at I mg/kg given 3 hr before the inflammogenic stimulus (n = 10).
In their classic studies, Di Rosa and his colleagues (9, 10) (13, 14) .
Many proteins or protein extracts have been reported to possess anti-inflammatory activity, but with few exceptions (e.g., superoxide dismutase) these proteins have never been completely characterized or the activity has been associated with endotoxin or reflex stimulation of the adrenal cortex (15) (16) (17) (18) . Endotoxin itself has been reported to have anti-inflammatory effects, but the ED50 in the rat paw edema test was 2-5 ,ug per paw-at least 103-fold greater than the amounts we administered (18) .
That human recombinant lipocortin 1 is anti-inflammatory is particularly significant because the glucocorticoids induce the lipocortin gene (5) . Other lines of evidence point indirectly to the importance of lipocortin as an important mediator of steroid action: inflammation and lipid-mediator release in adrenalectomized rats is greatly enhanced relative to sham-operated animals (19) , suggesting that endogenous lipocortin exerts a continual inhibitory tone. Autoantibodies to lipocortin have also been reported (20, 21) in the plasma of patients with chronic inflammatory diseases, and the titer of these antibodies seems to correlate positively with the clinical phenomenon of "steroid-resistance" (21) .
We believe that the synthesis and release of lipocortin may partially explain the marked anti-inflammatory actions of steroids and that after local administration of lipocortin, 
